TICKERNERD
Menu
RCKTRCKTHealthcare · Biotechnology

RCKT Stock Forecast: Rocket Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.63
+3.75% on the day

The 14 Wall Street analysts covering Rocket Pharmaceuticals, Inc. hold a median 12-month price target of $9.5 — +261.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$272.2M
Ticker Nerd rank
58 / 100
Median analyst target
$9.50
Analysts covering
14
Revenue$0.0
Operating income−$46.9M
Net income$123.2M
Free cash flow−$39.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.5%
1M
−29.1%
YTD
−25.1%
1Y
−22.4%
From 52W high
−50.4%
From 52W low
+6.0%
$2.48
$5.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RCKT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rocket Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
58 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
83
Size
62
Quality
61
Revisions
61
Issuance
51
Value
45
Momentum
43
Volatility
41
Accruals
39

Growth (83): Sales and profits are climbing, and climbing faster than before.

Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RCKT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RCKT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26RCKTHigh $15.00Median $9.50Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
7 Buy5 Hold2 Sell
Low $3.00Median $9.50High $15.00

The green dot is the last close — the median target sits +261.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Sept 2026NeedhamUpgradeBuy$9.00
16 Sept 2026WedbushReiteratesOutperform$15
15 Sept 2026Chardan CapitalMaintainsBuy$11
1 Sept 2026Chardan CapitalMaintainsBuy$11
1 Sept 2026Chardan CapitalMaintainsBuy—
11 Aug 2026WedbushMaintainsOutperform$16 → $15
11 Aug 2026WedbushMaintainsOutperform—
11 May 2026Chardan CapitalMaintainsBuy—
11 May 2026Chardan CapitalMaintainsBuy$11
30 Mar 2026B of A SecuritiesMaintainsBuy—
27 Mar 2026Chardan CapitalMaintainsBuy—
2 Mar 2026Goldman SachsMaintainsSell—
27 Feb 2026Cantor FitzgeraldMaintainsOverweight—
18 Nov 2025B of A SecuritiesMaintainsBuy—
18 Nov 2025JP MorganDowngradeUnderweight—
14 Oct 2025Chardan CapitalMaintainsBuy—
3 Oct 2025Leerink PartnersMaintainsMarket Perform—
20 Aug 2025B of A SecuritiesUpgradeBuy—
20 Aug 2025Chardan CapitalMaintainsBuy—
11 Aug 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCKT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RCKT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Rocket Pharmaceuticals, Inc. returned −22.4% against +16.2% for the S&P 500, dividends included.

RCKT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26RCKTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RCKT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Rocket Pharmaceuticals, Inc. (RCKT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−4.8%

Higher than 40% of US stocks

Return on assets
−28.4%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rocket Pharmaceuticals, Inc. (RCKT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rocket Pharmaceuticals, Inc. has a market value of $272.2M and an enterprise value of $13.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$17.3M.

  • Diluted earnings per share, trailing twelve months: $−0.17.

  • Free cash flow in the twelve months to 30 June 2026: −$170.4M.

  • Shares outstanding: 109.5M.

  • Trailing P/E: −1.2×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Rocket Pharmaceuticals, Inc. employs 202 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

RCKT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RCKTRocket Pharmaceuticals, Inc.$272.2M
58
LRMRLarimar Therapeutics, Inc.$285.1M
29
FULCFulcrum Therapeutics, Inc.$286.1M
38
ABEOAbeona Therapeutics, Inc.$283.0M
40
EYPTEyePoint, Inc.$286.4M
11
XFORX4 Pharmaceuticals, Inc.$276.6M
58
BNTCBenitec Biopharma, Inc.$294.5M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rocket Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RCKT news & analysis

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Proactive Investors · 7 Oct 2026positive

Rocket Pharmaceuticals shares rose 4% on Wednesday after the company secured access to up to $150 million through a credit facility with Hercules Capital. The facility is intended to support its pivotal Phase 2 RP-A501 study for Danon disease and its broader cardiovascular pipeline.

Why it matters — The facility provides additional capital for Rocket's clinical study and cardiovascular pipeline.

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Business Wire · 7 Oct 2026positive

Rocket Pharmaceuticals highlighted findings and development milestones for RP-A501 from its October 6 Danon disease investor webinar, including a defined path to completing an FDA-aligned pivotal Phase 2 trial and sustained biological activity in longer-term Phase 1 follow-up.

Why it matters — The update provides RCKT watchers with information on RP-A501’s clinical findings and the planned pivotal-trial path.

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

MarketBeat · 7 Oct 2026neutral

Rocket Pharmaceuticals outlined updated clinical, regulatory, and commercial plans for its investigational Danon disease gene therapy RP-A501. The update included longer-term Phase I findings, preliminary Phase II observations, and an FDA-aligned pivotal study design.

Why it matters — The update provides RCKT watchers with information on the therapy’s clinical progress and planned pivotal study.

FAQ

Frequently asked questions about RCKT stock

What is the RCKT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Rocket Pharmaceuticals, Inc. have a median 12-month price target of $9.5, with estimates ranging from $3 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RCKT stock a buy right now?

Of the 14 analysts covering Rocket Pharmaceuticals, Inc., 7 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Rocket Pharmaceuticals, Inc. 58 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RCKT?

As at 8 Oct 2026, Rocket Pharmaceuticals, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).

Will RCKT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +261.2% from the last close, and Ticker Nerd's factor model ranks Rocket Pharmaceuticals, Inc. 58 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RCKT stock forecast for 2030?

No analyst covering Rocket Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $15 over the next 12 months.

How has RCKT stock performed over the past year?

Rocket Pharmaceuticals, Inc. returned -22.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rocket Pharmaceuticals, Inc. do?

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology.

What is the latest news on RCKT?

The most recent item we track (Proactive Investors, 7 Oct 2026): "Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility". Rocket Pharmaceuticals shares rose 4% on Wednesday after the company secured access to up to $150 million through a credit facility with Hercules Capital. The facility is intended to support its pivotal Phase 2 RP-A501 study for Danon disease and its broader cardiovascular pipeline.

Company

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions. Rocket Pharmaceuticals currently develops and advances investigational and commercial genetic medicines, including therapies for disorders such as Danon disease, BAG3-related dilated cardiomyopathy, Fanconi anemia, and severe leukocyte adhesion deficiency-I. The company is also involved in manufacturing, clinical development, and the commercialization of its gene therapy products. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals plays a specialized role in the rare-disease market by targeting conditions with significant unmet medical need through precision genetic medicine.

CEO Dr. Gaurav D. Shah M.D. · 202 employees · United States · https://www.rocketpharma.com